Haleon is targeting U.S. consumers using GLP-1 weight-loss medications such as Wegovy and Zepbound. The maker of Advil and TUMS is partnering with retailers like CVS to place products in dedicated sections for GLP-1 users.
These products address common side effects including nausea and indigestion. This dual-placement strategy in both curated sections and regular aisles drove an average sales lift of 24% per store during the first quarter.
Haleon currently holds the majority of GLP-1-related shelf space at CVS. The initiative leverages the company's existing consumer health portfolio to capitalize on the growing weight-loss drug market.